Retrospective Study
Copyright ©The Author(s) 2025.
World J Stem Cells. Feb 26, 2025; 17(2): 100621
Published online Feb 26, 2025. doi: 10.4252/wjsc.v17.i2.100621
Table 2 Univariable analysis of 35 pediatric patients with high-risk neuroblastoma, n (%)
CharacteristicsTotal (n = 35)3-year OS
3-year EFS
mean ± SD
χ2
P value
mean ± SD
χ2
P value
Age
        < 36 months10 (28.6)100100
        ≥ 36 months25 (71.4)55.4 ± 12.24.850.03a51.3 ± 12.04.850.03a
Sex
        Male26 (74.3)71.8 ± 10.567.9 ± 10.7
        Female9 (25.7)57.1 ± 18.70.370.5457.1 ± 18.71.70.36
LDH
        < 1000 U/L25 (71.4)82.0 ± 8.177.4 ± 8.9
        ≥ 1000 U/L10 (28.6)30.0 ± 22.64.320.04a30.0 ± 22.63.150.08
MYCN
        Non-amplified23 (65.7)62.4 ± 14.057.9 ± 13.7
        Amplified5 (14.3)100100
        Unknown7 (20.0)57.1 ± 18.72.720.1057.1 ± 18.72.430.12
NSE
        < 200 ng/mL10 (28.6)70.0 ± 14.570.0 ± 14.5
        ≥ 200 ng/mL21 (60.0)68.8 ± 14.863.7 ± 14.5
        Unknown4 (11.4)50.0 ± 25.00.120.7350.0 ± 25.00.190.66